Insulin analogue glargine possibly increases cancer risk
Friday, June 26, 2009 - 16:14
in Health & Medicine
The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. The Institute for Quality and Efficiency in Health Care (IQWiG), in collaboration with the "Wissenschaftliches Institut der AOK" (WIdO), the research institute of the German Local Health Care Fund, analysed the data of almost 130,000 patients with diabetes in Germany who had been treated with either human insulin or the insulin analogues lispro (trade name: Humalog), aspart (Novorapid) or glargine (Lantus) between January 2001 and June 2005.
Read the whole article on Physorg
More from Physorg
Related
- Insulin analogue glargine possibly increases cancer riskFri, 26 Jun 2009, 17:16:37 EDT
- Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not provenFri, 3 Apr 2009, 9:38:26 EDT
- Insulin is a possible new treatment for Alzheimer'sMon, 2 Feb 2009, 17:23:31 EST
- Some patients may not need insulin for long-term control of type 2 diabetesMon, 16 Jun 2008, 1:36:06 EDT
- Trans-fatty acids and insulin sensitivityTue, 8 Jul 2008, 15:42:36 EDT